Health Care

China SXT Pharmaceuticals: A sharp plunge from a $1,047 peak to $2.46, a negative P/E, and mounting doubts on its future in Chinese personal‑care medicine.

Gilead Sciences shows steady growth in a volatile market, driven by a robust pipeline in HIV, liver and cardiovascular therapy, proving biotech resilience.

Verastem’s fight against cancer: a look at its volatile stock, RAF/MEK/FAK drug pipeline, and the high‑risk, high‑reward path to market success.

How TScan’s 75% workforce cut and shift to in‑vivo solid‑tumour T‑cell therapy is shaking its stock, investor sentiment, and future prospects.

Discover how ICON PLC, a $12.44 B pharma services leader, powers global clinical research, driving drug development with data, regulatory & lab expertise.

GSK launches phase‑III trial for its dual‑target mRNA flu vaccine, boasting stronger immune responses than licensed shots and positioning a potential market shift.

Fortrea Holdings Inc. faces steep stock decline and a negative P/E, yet it’s a key healthcare innovator. Can strategic shifts turn its financial woes into growth?

Genmab’s price target rises to DKK 2,500 as Q2 beats expectations and Phase III data loom—discover why analysts see rising upside and diversified revenue streams.

Definitive Healthcare Corp. stock slumps to $0.90, a sharp drop from $4.35 highs. Despite a $137.6 M market cap and global data‑analytics services, a negative P/E signals profit struggles. Investors watch as the health‑tech firm seeks recovery.

Discover how Novo Nordisk’s new leadership shake‑up, Wegovy pill rollout in Germany, and 2 mg Ozempic launch in Norway are reshaping the obesity drug market and driving investor upside.